Last reviewed · How we verify

NCT06560476: APEX

OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

Recruiting now Last updated 27 March 2026
What this trial tests

trial testing Data collection in Benign Prostatic Hyperplasia in 500 participants. Currently enrolling.

Timeline
30 March 2024
Primary endpoint
30 March 2027
30 March 2027

Quick facts

Lead sponsorUrotronic Inc.
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date30 March 2024
Primary completion30 March 2027
Estimated completion30 March 2027
Sites9 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Urotronic Inc. — full company profile →

Who can join

Eligibility, male only, with Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

Other recruiting trials for Benign Prostatic Hyperplasia

Currently open trials in the same condition.

Other Urotronic Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06560476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing